10

- 19. The composition of claim 18 wherein said pharmaceutically active agent is present in the composition in an amount of from about 1 wt. % to about 40 wt. %.
- **20**. The composition of claim 1 wherein said non-pH-dependent sustained release agent is present in the composition in an amount of from about 5 wt. % to about 50 wt. %.
- 21. The composition of claim 20 wherein said non-pH-dependent sustained release agent is present in the composition in an amount of from about 10 wt. % to about 30 wt. 10 %
- 22. The composition of claim 1 wherein said at least one pH-dependent agent is present in the composition in an amount of from about 0.5 wt. % to about 40 wt. %.
- 23. The composition of claim 22 wherein said at least one 15 pH-dependent agent is present in the composition in an amount of from about 1 wt. % to about 20 wt. %.
- 24. The composition of claim 8 wherein said non-pH-dependent sustained release agent is ethylcellulose.

- 25. The composition of claim 8 wherein said non-pH-dependent sustained release agent is hydroxypropyl methylcellulose.
- 26. The composition of claim 8 wherein said non-pH-dependent sustained release agent is an acrylate/methacrylate copolymer.
- 27. The composition of claim 8 wherein said non-pH-dependent sustained release agent is polyethylene oxide.
- 28. The composition of claim 9 wherein said at least one polymer that swells at a pH in excess of 5.5 is sodium alginate.
- 29. The composition of claim 10 wherein said at least one enteric agent is a methacrylic acid copolymer.
- **30**. The composition of claim **1** wherein said composition is in the form of a tablet.

\* \* \* \* \*